title: [Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease) accompanied by hemophagocytosis and salivary gland swelling in a patient with systemic lupus erythematosus].
abstract: After 2 years of steroid therapy that had effectively controlled her systemic lupus erythematosus, a 37-year-old woman presented with fever, erythema (face, upper chest), and low CH50. Increased oral steroid (prednisolone from 15 mg to 40 mg) and intravenous methylprednisolone (mPSL) (80 mg for 3 days) alleviated these symptoms except for the fever. Subsequently, the patient's fever worsened and leukocytopenia, abnormal liver function, lymphadenopathy (neck, axilla), and salivary gland swelling developed. Lymph node histology revealed features characteristic of Kikuchi-Fujimoto's disease (KFD). Laboratory examinations showed WBC 600/microliter, Hb 9.5 g/dl, platelets 90,000/microliter, GOT 766 IU/l, GPT 646 IU/l, LDH 4,228 IU/l, TG 1,622 mg/dl, and ferritin 6,330 ng/ml. Serum interferon gamma was also elevated (673 U/ml). Because a bone marrow smear revealed hemophagocytosis, mPSL pulse therapy (1 g for 3 days) was started for treatment of hemophagocytic syndrome. The fever promptly disappeared, and the patient's clinical symptoms resolved within 2 weeks. The abnormal laboratory data related to KFD and hemophagocytosis returned to normal within 4 weeks after the initiation of mPSL pulse therapy. We speculated that the hemophagocytosis and salivary gland involvement in this patient were also symptoms of KFD. This case indicated that corticosteroid pulse therapy is effective for KFD with serious clinical symptoms.
authors.affiliation: Department of Hematology and Immunology, Kanazawa Medical University.
authors.forename: Y
authors.initials: Y
authors.lastname: Wano
authors.forename: K
authors.initials: K
authors.lastname: Ebata
authors.forename: Y
authors.initials: Y
authors.lastname: Masaki
authors.forename: S
authors.initials: S
authors.lastname: Takeshita
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: C G
authors.initials: CG
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Hirose
authors.forename: T
authors.initials: T
authors.lastname: Tohyama
authors.forename: S
authors.initials: S
authors.lastname: Sugai
mesh_terms: D000328:Adult; D005260:Female; D020042:Histiocytic Necrotizing Lymphadenitis / Q000188:drug therapy / Q000209:etiology*; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D012793:Sialadenitis / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D011239:Prednisolone